Key takeaways
- A University of Zagreb group described the parent protein, BPC, in 1992 and the 15-amino-acid fragment BPC 157 in 1993; FDA staff say researchers there first synthesised it.
- BPC stands for body protection compound, the 1992 authors’ name for the parent protein: a label, not a finding about what BPC-157 does. Its codes include PL-10, PLD-116 and PL 14736, and FDA lists the name Bepecin.
- Of 234 PubMed records naming it, 175 list the Zagreb group’s Pavle Sikirić as an author (our count); the share has fallen to 62 of 109 since 2020.
- A clinical programme under PL 14736 in 2002–2005 is known only from meeting abstracts, and FDA staff judged its phase II data inadequate.
- WADA named it in 2022, FDA placed it in Category 2 in 2023, Australia scheduled it in 2024, and in 2026 HHS issued a compounding policy. None is an approval.
01BPC-157 history at a glance
A dated record, from the first paper to November 2026.
| Date | What happened |
|---|---|
| 1992 | A University of Zagreb group publishes on a “newly partially characterized gastric juice peptide” it calls body protection compound, or BPC. It is the earliest PubMed record we found that names it. |
| 1993 | The same group describes a 15-amino-acid fragment, BPC 157, as “fully characterized”. FDA staff, 2026: “Literature shows that BPC-157 was first described in 1993.” |
| 2001 | The phrase “stable gastric pentadecapeptide” first appears in PubMed titles and abstracts about it. |
| 2002–2005 | Clinical development under the code PL 14736: early safety studies and a phase II trial in ulcerative colitis, reported only as meeting abstracts. |
| 2006 | A Zagreb paper links BPC 157 to the codes PL-10, PLD-116 and PL 14736 and to Pliva, Croatia. |
| Dec 2015 | The first ClinicalTrials.gov record (NCT02637284, phase 1) is posted. Its status is unknown, with no posted results. |
| 2017 | A US anti-doping laboratory reports BPC 157 identified in confiscated vials and publishes a urine test for it. |
| 30 Sep 2021 | WADA publishes its 2022 Prohibited List, naming BPC-157 in class S0. It is the first substance named by example in that class. The List takes effect on 1 January 2022. |
| Sep 2023 | FDA places BPC-157 in Category 2 of its compounding policies, for bulk substances that may present significant safety risks. |
| 1 Jun 2024 | Australia: Schedule 4 and Appendix D entries take effect, after the TGA’s final decision of 22 May 2024. |
| 13 Apr 2026 | A TGA safety advisory lists BPC-157 among examples of unapproved peptide products. |
| 22 Apr 2026 | BPC-157 leaves Category 2. HHS later notes that neither the placement nor the removal changed its status under section 503A. |
| 23 Jul 2026 | FDA’s Pharmacy Compounding Advisory Committee votes in favour of adding it to the 503A bulks list. FDA’s drug centre had recommended against. The vote is advice, not a rule. |
| 28 Oct 2026 | HHS issues an enforcement-discretion policy for compounding BPC-157 acetate by licensed pharmacies and physicians on prescription, under conditions. It is not an approval, and products sold as research chemicals are outside it. |
| Nov 2026 | Not an approved medicine. In their 2026 review, a database search by FDA staff found no approved product containing it in any country. |
02Where did BPC-157 come from?
BPC-157 began in a pharmacology department at the University of Zagreb, Croatia. In 1992 a group whose papers list Pavle Sikirić as first author described a protein from gastric juice, which it called body protection compound, or BPC. The paper called it “newly partially characterized”. In 1993 the group’s overview reported that this protein, of about 40,000 daltons, had been “recently isolated”, and that a 15-amino-acid fragment, named BPC 157, had been “fully characterized”.
FDA staff, reviewing it in 2026, put it this way: BPC-157 “was first synthesized by researchers at University of Zegreb [sic], Republic of Croatia, in the early 1990s”, and it is “reported to be a pentadecapeptide fragment of BPC” that “has been found in gastric juice”. They add that in 1993 it was described as made by stepwise solid-phase synthesis and purified by HPLC to a purity above 95%. BPC-157 is a synthetic 15-amino-acid peptide.
The first studies were in rats, in models of stomach, duodenal and liver lesions. Those are animal models (T3). They are where the research started, not evidence about people.
03What is BPC-157’s structure?
BPC-157 is a pentadecapeptide: a chain of 15 amino acids. Its sequence, as HHS’s 2026 policy appendix gives it, is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written in one-letter code as GEPPPGKPADDAGLV.
- Free base. Formula C62H98N16O22, molecular weight 1,419.5 g/mol (FDA, 2026).
- Acetate salt. HHS gives 1,419.54 g/mol plus the acetate, and its 2026 policy covers this form.
- Which form a study used. FDA staff evaluated both, and noted that most studies do not say which form they used.
That matters for anyone reading the literature: a result for one salt form is not automatically a result for another. More: peptide salt forms and how identity is checked by mass spectrometry.
04How did BPC-157 get its name?
BPC. The letters come from the 1992 paper’s name for the parent protein, body protection compound. FDA’s 2026 briefing still opens with that expansion. The name is the authors’ label, not a finding about what the peptide does.
157. The papers we read do not explain the number.
Stable gastric pentadecapeptide. From 2001 the group’s titles and abstracts often call it “stable gastric pentadecapeptide BPC 157”. Of the 118 PubMed records using that phrase, 114 list Sikirić as an author (our count, 18 November 2026).
Development codes. A 2006 paper from the group gives the codes PL-10, PLD-116 and PL 14736, with “Pliva, Croatia”. FDA staff list two other names: “BPC-157 is also known as Bepecin or PL-14736”.
Spelling. The Zagreb papers mostly write “BPC 157”. Regulators and WADA write “BPC-157”. They are the same peptide.
05How did research on BPC-157 develop?
Mostly in one group’s laboratories, and mostly in animals. The share of papers listing that group’s lead author has fallen this decade.
| Years | PubMed records naming it | With Pavle Sikirić as an author |
|---|---|---|
| 1993–1999 | 22 | 21 |
| 2000–2009 | 42 | 39 |
| 2010–2019 | 61 | 53 |
| 2020–18 Nov 2026 | 109 | 62 |
| All years | 234 | 175 (75%) |
Our count from a PubMed title and abstract search for BPC-157, BPC 157, BPC157, bepecin, PL 14736 and “pentadecapeptide BPC”, by publication date, run 18 November 2026. The percentage is our calculation.
1990s: one group. 21 of the 22 records list Sikirić as an author.
2002–2005: a clinical programme. Under the code PL 14736, early safety studies and a phase II trial in ulcerative colitis were run. All three are known only from meeting abstracts. FDA staff judged that trial’s data “inadequate to support the efficacy and safety” of BPC-157 as the trial gave it. We found no published phase III trial.
2010s: more animal models. The literature grew, still mostly from Zagreb (53 of 61 records list Sikirić) and mostly in animals, as later reviews found.
2020s: more groups, and reviews. Records this decade already outnumber the 1990s and 2000s together, and 47 of the 109 do not list Sikirić. Independent reviewers have weighed the evidence. A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical. A 2026 systematic review of the three full human papers rated the certainty of the evidence “very low”. In July 2026, FDA staff concluded there is “insufficient clinical safety information to characterize the safety profile” of BPC-157.
Trials. ClinicalTrials.gov lists four records: one first posted in 2015 and three in 2026. None has posted results (18 November 2026). Every study we found that gave it to people: BPC-157 human studies. The evidence today: BPC-157 research guide.
06How have regulators treated BPC-157?
In the record below, sport moved first, in 2021; the medicines-regulator steps start in 2023. In 2026, FDA’s drug centre and its advisory committee disagreed.
Sport. On 30 September 2021 WADA published its 2022 List and wrote: “For the first time, a substance has been included by name as an example in section S0”. That substance was BPC-157, which WADA called “an experimental peptide sold as a supplement”. It is still named in the 2026 and 2027 Lists. Detail: peptides and anti-doping.
United States. HHS’s 2026 policy appendix records that BPC-157 was in Category 2 “from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A”. It adds that FDA’s drug centre “recommended against listing either form, and the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of inclusion”. HHS then issued its enforcement-discretion policy in October 2026. None of this is an approval. Full record: is BPC-157 legal? and the 2026 committee vote.
Australia. The TGA scheduled BPC-157 in Schedule 4, prescription-only, and in Appendix D, from 1 June 2024. Its decision notices recorded “no currently approved products containing BPC-157 in Australia”. In April 2026 a TGA advisory listed it first among examples of unapproved peptide products.
Approval. In their July 2026 review, a database search by FDA staff found no approved product containing BPC-157 in any country. More than 30 years after the first paper, it is not an approved medicine.
07What we don’t know about BPC-157’s history
- The full structure of the parent protein, BPC. The 1992 paper calls it partially characterised, and the papers we read do not give its sequence.
- What the number 157 stands for.
- Why the PL 14736 programme stopped. We found no published phase III trial and no statement explaining it.
- The full results of the early human studies, known only from meeting abstracts.
- How much of the animal literature independent groups have repeated. Three in four PubMed records list one author from one group.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.